gemcitabine has been researched along with 1-methylpropyl-2-imidazolyl disulfide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Abbruzzese, J; Baker, AF; Dragovich, T; Green, S; Guillen, JM; Kirkpatrick, L; Pestano, LA; Ramanathan, RK; Von Hoff, DD | 1 |
1 review(s) available for gemcitabine and 1-methylpropyl-2-imidazolyl disulfide
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
1 trial(s) available for gemcitabine and 1-methylpropyl-2-imidazolyl disulfide
| Article | Year |
|---|---|
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Disulfides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Mas; Survival; Thioredoxins; Treatment Outcome | 2011 |